ELMO2

Across TCGA pan-cancer cohorts, ELMO2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ELMO2 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ELMO2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ELMO2 expression acts as an unfavorable survival marker.

PDAC, CCRCC, and UCEC are the cancer types where ELMO2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.281	0.499	<.001	43	view →
CCRCC	OS	Tertile	III,IV	0.725	1.000	.009	33	view →
UCEC	DFS	Tertile	III,IV	0.298	1.000	.011	24	view →
LSCC	DFS	Quartile	II,III,IV	0.462	0.894	.003	8	view →
COAD	DFS	Quartile	III,IV	0.778	1.000	.046	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ELMO2–PDAC (DFS)

Open the PDAC breakdown →